On 2 March 2016, a Soyuz spacecraft touched down on the frozen steppe of Kazakhstan. Inside was Scott Kelly, the first American to spend a year in space – 340 days aboard the International Space Station. NASA scientists had expected him to emerge triumphant, a testament to human resilience. What they found was closer to a medical emergency. His ankles were swollen to the size of basketballs. A raw rash covered his skin. Clothes touched him like sandpaper. Inflammation markers in his blood – the body’s emergency alarm signals – were at levels his doctors had only ever seen in patients who had just survived a heart attack.
“It was the highest value I had ever seen,” said one NASA physician reviewing the data.
Kelly’s year-long mission was not merely an endurance test. It was the centrepiece of the NASA Twins Study, the most comprehensive examination of human spaceflight ever conducted, comparing Scott in orbit with his identical twin brother Mark on Earth. Ten research teams across the United States monitored everything from gene expression to gut bacteria to cognitive function. The results, published in the journal Science in 2019, told a story far stranger and more unsettling than anyone had anticipated.
The Experiment That Changed Everything
The logic of the Twins Study was elegant. Identical twins share the same DNA, the same genetic starting point. If you put one in space and keep the other on Earth, you strip away the noise of individual variation. What remains is the signature of space itself, written on the body in molecular detail.
Scott Kelly launched on 27 March 2015 alongside Russian cosmonaut Mikhail Kornienko. Their mission, formally designated the ISS Year-Long Mission, was designed as a stepping stone toward Mars – a three-year round trip that remains humanity’s most ambitious exploration target. For nearly a year, Kelly lived in microgravity, conducting nearly 400 investigations while his twin brother Mark, also a retired astronaut, submitted to identical tests on the ground.
What the researchers discovered, as Weill Cornell geneticist Christopher Mason later described in his book The Next 500 Years, was that Kelly’s body did not simply endure space. It adapted to it – and then rebelled upon return.
The Telomere Paradox
Among the most bewildering findings was what happened to Kelly’s telomeres – the protective caps at the ends of chromosomes that shorten as we age. The scientific consensus was clear: space radiation, stress, and the harsh environment of orbit should accelerate telomere shortening. That did not happen. During his 340 days in space, Kelly’s telomeres grew 14.5 per cent longer than his brother’s, according to Susan Bailey, a radiation cancer biologist at Colorado State University who led the telomere investigation.
The discovery upended expectations. Longer telomeres are typically associated with cellular youth, with health. Kelly, in a sense, had got younger at a chromosomal level while orbiting the Earth at 17,500 miles per hour.
But the benefit was an illusion. Within 48 hours of touching down, Kelly’s telomeres began shrinking. Within weeks, they were shorter than before the mission. “The fountain of youth was a mirage,” Mason wrote. Or worse, a trap – a rapid reversal that left his chromosomes more vulnerable than they had been before launch.
The precise mechanism remains unknown. Bailey and her colleagues have speculated that the strict diet, daily exercise, and controlled environment of the space station may have temporarily boosted telomerase, the enzyme that rebuilds telomeres. But the collapse upon re-entry suggests the body’s repair systems were overwhelmed by the reintroduction of gravity and the inflammatory shock of return.
A Body at War With Itself
The telomere story was only part of the picture. Upon Kelly’s return, his body mounted what can only be described as an immune overreaction. Inflammatory cytokines – proteins that coordinate the body’s defence against infection and injury – surged to extraordinary levels. According to the integrated multi-omics analysis team that synthesised data from all ten research groups, three strong indicators of systemic inflammation were detected in Kelly while he was still in space.
Most striking was the intensity of the post-flight response. The carotid arteries, which supply blood to the brain, had thickened measurably during the mission and immediately after landing. This pattern mirrors what physicians see in patients with early-stage cardiovascular disease. Whether the changes proved reversible remained an open question – the study ended before conclusive answers emerged.
His gut microbiome was “profoundly different” during flight from its pre-mission state. The freeze-dried, thermo-stabilised food aboard the station, combined with the stress of microgravity, altered the composition and diversity of his intestinal bacteria. Unlike some of the other changes, this one did normalise after his return to Earth.
His body mass dropped by seven per cent, partly because he consumed roughly 30 per cent fewer calories than anticipated. His folate levels, paradoxically, improved – he ate better in space than many people do on the ground, thanks to the structured nutrition programme. Yet even this positive outcome carried a footnote: folate status appeared to correlate with the telomere dynamics that so confounded researchers.
The Cognitive Shadow
Perhaps the most insidious finding concerned Kelly’s mental performance. During his time in space, cognitive tests showed his alertness, spatial orientation, and emotional recognition remained largely stable. This was encouraging news for agencies planning multi-year missions. But after landing, a pronounced decline in speed and accuracy appeared – and it persisted for six months.
The implications are sobering. An astronaut returning from Mars would face not only the physical ordeal of re-entry and gravity’s return, but also a cognitive deficit at precisely the moment when mission demands – vehicle operation, emergency procedures, crew coordination – are at their most critical. The Twins Study data suggested that the human brain, like the body, needs time to readjust to Earth. And that readjustment period might overlap with the most dangerous phase of any return journey.
From Kelly to the Moon: Artemis II and the New Frontier of Space Medicine
Kelly’s 340-day mission produced the deepest biological dataset in spaceflight history. But the science did not stop there. In April 2026, four astronauts – Reid Wiseman, Victor Glover, Christina Koch, and Canadian Jeremy Hansen – launched aboard Artemis II, the first crewed mission beyond low-Earth orbit since Apollo 17 in 1972.
Artemis II was designed as a 10-day lunar flyby, not a long-duration stay. But it carried a suite of health experiments that built directly on the lessons of the Twins Study. The ARCHeR (Artemis Research for Crew Health and Readiness) wearable sensors tracked sleep, activity, and stress in real time, providing continuous data streams rather than the periodic snapshots that had characterised earlier research. The AVATAR experiment, developed by Harvard’s Wyss Institute, used organ-on-a-chip technology – miniature devices containing living human cells derived from the crew’s own bone marrow – to model how radiation and microgravity affect tissue at the cellular level. “By sending patient-specific avatars of astronaut tissues into space, we can study risks in a personalised way never before possible,” said David Chou, a principal scientist at the Wyss Institute.
The crew also collected blood, saliva, and urine samples for immune biomarker analysis, built on the framework established by the Twins Study. These samples will be analysed over the coming months, with results expected to reshape protocols for future deep-space missions.
The Biology Problem
The pattern that emerges from Kelly’s mission through Artemis II is consistent: the engineering challenges of space travel, while formidable, are yielding to human ingenuity. Rockets launch. Spacecraft navigate. Modules dock. But the human body – the biological machine that must actually live, think, and function in environments it was never designed for – remains the most unpredictable variable.
Astronauts lose between 1 and 1.5 per cent of bone density per month in microgravity. After a six-month ISS mission, only about a third of astronauts recover their pre-flight hip bone density within a year. Radiation exposure on deep-space missions exceeds the legal limits NASA has set for astronaut cancer risk. The problem extends beyond human biology into the geopolitics of deep-space infrastructure, where nations including China are already staking claims to orbital tourism and lunar resources – ventures that will only accelerate the demand for reliable space medicine. A 2025 study from Cedars-Sinai estimated that astronauts aged nearly two years during just a nine-day stay on the station – an acceleration that speaks to the biological cost of weightlessness.
“We think of ourselves as adaptable, as minds that can conquer any environment with technology,” Mason wrote. “But our bodies are still just a collection of ancient biological processes that have no idea what space is.”
The contradiction is fundamental. Humanity is building the rockets to reach Mars. The question is whether the body inside the rocket can survive the journey – and whether, upon arrival, it can still function. The Twins Study showed that most of Kelly’s gene expression changes reverted to baseline after his return. But a small subset persisted for months. Carotid thickening lingered. Cognitive deficits endured. The telomere roller-coaster continued long after he had traded his spacesuit for a wheelchair on the Kazakh steppe.
What Comes Next
NASA’s Human Research Program now identifies five hazards of human spaceflight: space radiation, isolation and confinement, distance from Earth, gravity fields, and hostile closed environments. Each is being studied in detail – part of a broader scientific reckoning with the invisible forces that shape human survival, whether on Earth or beyond it. But the most important lesson from Scott Kelly’s year in space may be the simplest: the body does not negotiate. It adapts when it must, and it rebels when it can.
As the Artemis programme builds toward sustained lunar presence and eventual Mars missions, the biological data accumulated since 2015 will form the foundation of every crew health protocol. The organ-on-a-chip experiments, the wearable sensors, the immune biomarker panels – all of these trace their lineage back to a single, bruised astronaut stumbling out of a Soyuz capsule in Kazakhstan, his skin burning, his blood screaming with inflammation, his telomeres telling a story nobody could yet read.
The heroic narrative of space travel – the gleaming suits, the slow-motion glove floating in zero gravity – has always been a useful fiction. The reality is messier, more painful, and more profoundly human. Scott Kelly went to space to push the limits of exploration. What he discovered was that the limits are not out there, in the vacuum and the radiation and the distance. They are in us. In every cell, every chromosome, every ancient biological process that has spent four billion years learning to live on one planet and one planet only.
